Schölmerich, Jürgen, Fellermann, Klaus, Seibold, Frank W., Rogler, Gerhard, Langhorst, Jost, Howaldt, Stefanie, Novacek, Gottfried, Petersen, Andreas Munk 
, Bachmann, Oliver , Matthes, Harald, Hesselbarth, Norbert, Teich, Niels, Wehkamp, Jan, Klaus, Jochen, Ott, Claudia, Dilger, Karin, Greinwald, Roland and Mueller, Ralph
(2016)
A Randomised, Double-blind, Placebo-controlled Trial ofTrichuris suisova in Active Crohn’s disease.
Journal of Crohn's and Colitis, jjw184.
Full text not available from this repository.
at publisher (via DOI)
Other URL: http://doi.org/10.1093/ecco-jcc/jjw184
Abstract
Background and Aims: To investigate the efficacy and safety of three different dosages of embryonated, viable eggs of Trichuris suis [TSO] versus placebo for induction of remission in mildly-to-moderately active ileocolonic, uncomplicated Crohn's disease [CD]. Methods: Adults with active CD [n = 252] randomly received six fortnightly doses of 250, 2500, or 7500 TSO/15 ml suspension/day [TSO 250, ...
Abstract
Background and Aims: To investigate the efficacy and safety of three different dosages of embryonated, viable eggs of Trichuris suis [TSO] versus placebo for induction of remission in mildly-to-moderately active ileocolonic, uncomplicated Crohn's disease [CD]. Methods: Adults with active CD [n = 252] randomly received six fortnightly doses of 250, 2500, or 7500 TSO/15 ml suspension/day [TSO 250, TSO 2500, TSO 7500], or 15 ml placebo solution/day, in a double-blind fashion, with 4 weeks' follow-up. Primary endpoint was the rate of clinical remission [Crohn's Disease Activity Index [CDAI] < 150] at end of treatment, ie at Week 12 or withdrawal. Secondary endpoints included the course of clinical remission, rate of clinical response, change in CDAI, change in markers of inflammation, mucosal healing, and Physician's Global Assessment. Results: Clinical remission at Week 12 occurred in 38.5%, 35.2%, and 47.2% of TSO 250, TSO 2500, and TSO 7500 patients, respectively, and in 42.9% of placebo recipients. TSO induced a dose-dependent immunological response. There was no response regarding laboratory markers of inflammation. Other secondary efficacy variables also showed no advantage of TSO over placebo for treatment of active CD. Administration of TSO did not result in any serious adverse drug reaction. Review of non-serious suspected adverse drug reactions following TSO did not reveal any safety concerns. Conclusions: Administration of 250-7500 TSO fortnightly over 12 weeks was safe and showed a dose-dependent immunological response, but no TSO dose showed a clinically relevant effect over placebo for induction of clinical remission or response in mildly-to-moderately active, ileocolonic CD.
Export bibliographical data
| Item type: | Article |
|---|
| Date: | 2016 |
|---|
| Institutions: | Medicine > Lehrstuhl für Innere Medizin I |
|---|
| Identification Number: | | Value | Type |
|---|
| 10.1093/ecco-jcc/jjw184 | DOI |
|
|---|
| Keywords: | INFLAMMATORY BOWEL DISEASES; HELIGMOSOMOIDES-POLYGYRUS; ULCERATIVE-COLITIS; ACTIVITY INDEX; IMMUNE-SYSTEM; INFECTION; AUTOIMMUNE; THERAPY; HYGIENE; PARASITES; Crohn's disease; randomized; Trichuris suis ova [TSO] |
|---|
| Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine |
|---|
| Status: | Published |
|---|
| Refereed: | Yes, this version has been refereed |
|---|
| Created at the University of Regensburg: | Yes |
|---|
| Item ID: | 39145 |
|---|
Altmetric